BioAlliance Pharma unveils €16M rights issue
This article was originally published in Scrip
Executive Summary
BioAlliance Pharma, the Paris-based specialty and orphan oncology company, is intending to raise €16 million through the issue of 3,395,943 shares at €4.90 each. The capital raised will be used to continue development of Livitag (Doxorubicin Transdrug) to treat primary liver cancer, secure additional orphan assets, and longer term consider strategic commercialisation options in some territories. Holders of existing shares will be able to buy one share for every four they already own.